Company news

Immunome, Inc. news in 2026

Immunome, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Immunome to Present at Guggenheim 3rd Annual Healthcare Innovation Conference

November 2, 2026

Immunome Announces EMA Validation of Marketing Authorization Application for Varegacestat for the Treatment of Adults with Desmoid Tumors

October 30, 2026

Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026

October 26, 2026

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 6, 2026

Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors

September 30, 2026

Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference

September 2, 2026

Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update

August 11, 2026

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors

July 20, 2026

Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors

July 8, 2026

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors

June 11, 2026

Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting

May 29, 2026

Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

May 27, 2026

Immunome Reports First Quarter 2026 Financial Results and Provides Business Update

May 12, 2026

Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors

April 29, 2026

Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting

April 20, 2026

Immunome Reports Full Year 2025 Financial Results and Provides Business Update

March 3, 2026

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 4, 2026

Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

February 3, 2026

Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference

January 5, 2026

Decks in 2026